Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED
Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub 
Via Benzinga
News headline image
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
News headline image
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents ↗
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) 
Via Benzinga
Topics Intellectual Property
News headline image
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
News headline image
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business ↗
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. 
Via Benzinga
News headline image
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement ↗
Short-acting psychedelics biotech Small Pharma Inc. 
Via Benzinga
News headline image
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
News headline image
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution 
Via Benzinga
News headline image
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗
Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. 
Via Benzinga
News headline image
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
News headline image
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗
New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. 
Via Benzinga
News headline image
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Small Pharma Inc.
Via GlobeNewswire
News headline image
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression ↗
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... 
Via Benzinga
News headline image
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN). 
Via Benzinga
News headline image
Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT ↗
The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and... 
Via Benzinga
Topics Intellectual Property
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka... 
Via Benzinga
News headline image
Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M ↗
Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9... 
Via Benzinga
News headline image
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety ↗
Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o 
Via Benzinga
News headline image
Cybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for... 
Via Newsfile
Topics Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’
Via Investor Brand Network
Topics Intellectual Property
News headline image
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.